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Abstract Folates act as co-factors for transfer of one-
carbon units for nucleotide production, methylation and
other biosynthetic reactions. Comprehensive profiling of
multiple folates can be achieved using liquid chromatogra-
phy tandem mass spectrometry, enabling determination of
their relative abundance that may provide an indication of
metabolic differences between cell types. For example, cell
lines exposed to methotrexate showed a dose-dependent
elevation of dihydrofolate, consistent with inhibition of
dihydrofolate reductase. We analysed the folate profile of
E. coli sub-types as well as cell lines and embryonic tissue
from both human and mouse. The folate profile of bacteria
differed markedly from those of all the mammalian samples,
most notably in the greater abundance of formyl tetrahy-
drofolate. The overall profiles of mouse and human fibro-
blasts and mid-gestation mouse embryos were broadly
similar, with specific differences. The major folate species
in these cell types was 5-methyl tetrahydrofolate, in contrast
to lymphoblastoid cell lines in which the predominant form
was tetrahydrofolate. Analysis of embryonic human brain
revealed a shift in folate profile with increasing develop-
mental stage, with a decline in relative abundance of dihy-
drofolate and increase in 5-methyl tetrahydrofolate. These
cell type-specific and developmental changes in folate
profile may indicate differential requirements for the various
outputs of folate metabolism.
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Introduction
Folate one-carbon metabolism (FOCM) comprises a net-
work of interlinked reactions in which folates act as co-
factors for transfer of one-carbon units required in various
biosynthetic reactions (Fig. 1) [1–3]. Major functions of
FOCM are in production of purines and pyrimidines for
biosynthesis of nucleic acids, cysteine production and
provision of the methyl group in methylation of DNA,
RNA, proteins and lipids as well as synthesis of creatine
and phosphatidylcholine. Circulating folate is principally in
the form of 5-methyltetrahydrofolate (5-methyl THF).
Cellular uptake is mediated by folate receptors (FOLR1
and FOLR2) and the reduced folate carrier (RFC;
SLC19a1) and in the gut by the proton-coupled folate
transporter (PCFT; SLC46A1)[4]. Embryonic lethality of
mice lacking Folr1 or Rfc demonstrates the necessity of
folate uptake for postimplantation development [5–7].
Abnormalities in FOCM have been implicated in a
variety of pathological conditions including cancer, neural
tube defects (NTDs), cardiovascular disease, anaemia and
neurological conditions [3, 8–11]. Notably FOCM is
implicated in diseases that may occur throughout life,
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including birth defects that arise during early development.
For example, maternal supplementation with folic acid
reduces the risk of NTDs whilst sub-optimal folate status
and elevated homocysteine are associated with increased
predisposition to an affected pregnancy (reviewed in [9]).
The observation of defective thymidylate biosynthesis in
some human NTD cases and mouse models [12–14] sup-
ports the hypothesis that altered FOCM may contribute to
development of NTDs. Folate status has also been inves-
tigated in relation to risk of several different cancers,
colorectal cancer being probably the most intensively
studied. Epidemiological studies have shown an associa-
tion of low folate intake with risk of colorectal adenomas
and cancer, and use of folic acid supplements has been
reported to reduce risk and mortality. However, folic acid
supplements may also promote progression of pre-existing
preneoplastic lesions, thereby increasing cancer risk
[10, 15]. A similar non-linear relationship, in which both
low and high folate intake are associated with risk, has also
been reported for postmenopausal breast cancer [16].
The multiple outputs of FOCM imply several different
biochemical mechanisms by which impaired function may
influence embryonic development and post-natal patholo-
gies. Nucleotide biosynthesis is essential to support DNA
replication and cell proliferation, which may be of partic-
ular relevance to embryonic development, whilst impaired
thymidylate biosynthesis causes an increase in erroneous
incorporation of uracil into nuclear DNA [1]. The supply of
methyl groups is also required for cellular methylation
reactions and may impact DNA methylation, possibly
leading to altered transcriptional regulation. In this context,
there is increasing evidence of a potential link between
FOCM and the foetal epigenome, although whether altered
methylation contributes to birth defects has yet to be
established [17].
Alterations in FOCM can be investigated by analysis of
downstream biomarkers such as homocysteine concentration,
DNA methylation and uracil incorporation [1]. Mathematical
modelling also allows predictions of the effects of folate
status or enzyme inhibition on methylation and nucleotide
biosynthesis [18, 19]. It will also be informative to directly
quantify FOCM intermediates to evaluate possible alteration
in the ratio of abundance of individual metabolites that may
reflect disturbance of a particular step(s). For example,
10-formyl-THF provides one-carbon units for purine bio-
synthesis and a reduced abundance of this metabolite, relative
to its precursor THF, could lead to diminished purine syn-
thesis. Similarly, alteration in the relative abundance of
5-methyl THF may be informative about the contribution of
methyl groups to the methylation cycle.
Folates are transported into cells in the monoglutamated
form and multiple glutamate residues are then added by the
action of folylpolyglutamate synthetase. Polyglutamation is
required for cellular retention of folates and an optimal
analytical approach should therefore distinguish these
forms. Previously, we used liquid chromatography tandem
mass spectrometry (LC–MS/MS) for quantification of s-
adenosyl methionine (SAM) and s-adenosylhomocysteine
(SAH) in order to identify perturbations in the methylation
cycle [20, 21]. In the current study, we applied LC–MS/MS
to analyse FOCM intermediates in bacteria and for com-
parison of human and mouse cell lines and embryonic




Folate standards including dihydrofolate (DHF), tetrahy-
drofolate (THF), 5,10-methylene THF, 5-formyl-THF, 5,10-
methenyl THF, 5-methyl THF, folic acid (PteGlu), PteGlu3,
PteGlu4, PteGlu5, PteGlu7 and methotrexate were pur-
chased from Schircks Laboratories (Switzerland). Remain-
ing reagents were methanol, acetonitrile (Fisher Scientific,
UK), ammonium acetate, ascorbic acid, DTT, citric acid
(Sigma-Aldrich) and N,N-dimethylhexylamine (Fluka).
Samples for analysis
Bacteria OP50 and HT115 Escherichia coli strains [22–24]
were grown overnight in LB from a single colony at 37 C.
NGM plates [24] were seeded with 150 lL bacterial sus-
pension and incubated for 96 h at 20 C. Bacterial lawns
Fig. 1 Summary diagram of folate one-carbon metabolism. Folates
provide co-factors for the transfer of one-carbon units required for
production of pyrimidines, purines and remethylation of homocyste-
ine to methionine. Folates analysed in the current study are
underlined, whilst methodology for quantification of SAM and SAH
(dashed underline) was reported previously [20]
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were washed from the plates using M9, collected by cen-
trifugation at 4 C, 4,000 rpm for 20 min and the bacterial
pellet stored at -80 C prior to analysis. Cell lines EBV-
transformed human lymphocytes were collected with
ethical permission from normal Swedish individuals
(Karolinska Institutet). Cells were cultured in RPMI 1640
media with 10 % FCS. For LC–MS/MS analysis, 2 9 107
cells were harvested, washed in PBS and cell pellets stored
at -80 C prior to sample preparation. Human tissue was
obtained as frozen samples (at -80 C) from the human
developmental biology resource (www.hdbr.org). Mice
wild-type (CBA/Ca and C57BL/6) strain mice were mated
and mouse embryos were collected at embryonic day
(E) 12.5 [25]. Embryos were immediately frozen on dry ice
and stored at -80 C.
Sample preparation
Buffer containing 20 mM ammonia acetate, 0.1 % ascorbic
acid, 0.1 % citric acid and 100 mM DTT at pH 7 was
added to cells, tissues or embryos. Where quantitation was
performed, 3 ll of 10 lM methotrexate was added as
internal standard. Sample suspensions were sonicated for
10 s using a hand-held sonicator at 40 % amplitude. A
10 ll aliquot of each of the homogenised samples was
removed for DNA quantification using NanoDrop (thermo
scientific). Protein was removed by precipitation by addi-
tion of 2 sample volumes of acetonitrile, mixing for 2 min
and centrifugation for 15 min at 12,0009g and 4 C.
Supernatants were transferred to fresh tubes, lyophilised
and stored at -80 C prior to analysis.
LC–MS/MS
Lyophilised samples were resuspended in 50 ll water
(milli-Q) and centrifuged for 5 min at 12,0009g at 4 C.
Supernatants were transferred to glass sample vials for LC–
MS/MS analysis. Metabolites were resolved by reversed-
phase chromatography (Luna C18 column; 150 9 2.0 mm2;
5 lm bead size; Phenomenex, UK) using a 2795XE high
performance liquid chromatography unit with solvent divert
valve (Waters Corporation, UK). Solvents for HPLC were:
Buffer A, 5 % methanol, 95 % Milli-Q water and 5 mM
dimethylhexylamine at pH 8.0; Buffer B, 100 % methanol,
5 mM dimethylhexylamine. The column was equilibrated
with 95 % Buffer A: 5 % Buffer B. The sample injection
volume was 40 ll. The HPLC protocol consisted of 95 %
Buffer A: 5 % Buffer B for 1 min, followed by a gradient of
5–60 % Buffer B over 9 min and then 100 % Buffer B for
6 min before re-equilibration for 4 min. The metabolites
were eluted at a flow rate of 200 nl/min. The HPLC was
coupled to a triple quadrupole tandem mass spectrometer
(MicroMass Quattro, Waters Corporation, UK) operating in
negative-ion mode using the following settings: capillary
3.54 kV, source temperature 150 C, desolvation tempera-
ture 350 C, cone gas flow rate 25 l/h and desolvation gas
flow rate 950 l/h. Folates were measured by multiple reac-
tion monitoring (MRM) with optimised cone voltage and
collision energy for precursor and product ions (based on
[26]).
Data analysis and statistics
The peak areas of individual folates were extracted using
MassLynx software (Waters). The total peak area of each
folate (sum of mono- and polyglutamated forms) was
expressed as a percentage of the total folate in each sample.
Data were analysed using SigmaStat (Systat Software,
Version 3.5). Pairwise comparisons were made by t test,
and multiple comparisons by one way ANOVA with Holm-
Sidak post hoc test.
Results
In order to allow analysis of multiple folate species, we
first determined optimal MRM conditions for detection of
individual folate standards, based on reported MS param-
eters [26]. Thus, MRMs were determined for mono-gluta-
mated forms of THF, 5-formyl-THF (CHO-THF), 5-methyl
THF (5-CH3 THF), 5,10-methylene THF (5,10-CH2 THF),
5,10-methenyl THF (5,10-CH THF) and DHF, together
with multiple glutamated forms of folic acid with 1, 3, 4, 5
and 7 glutamates (Table 1). These characteristic MRMs
Table 1 MRM values for folate standards
Folate MRM transition (m/z)
Monoglutamates
5-Formyl THF 472.17 [ 314.95
5-Methyl THF 458.19 [ 328.89
5,10-Methylene THF 456.28 [ 326.98
5,10-Methenyl THF 454.00 [ 281.00
THF 444.20 [ 314.85
DHF 441.97 [ 175.99
Folic acid: mono and polyglutamates
PteGlu (folic acid) 440.05 [ 310.86
PteGlu3 698.37 [ 421.99
PteGlu4 827.52 [ 422.02
PteGlu5 956.67 [ 422.03
PteGlu7 606.84 [ 422.02
The MRM transitions (precursor [ product ion) are indicated for each
of the monoglutamated folate standards as well as polyglutamated
forms of folic acid. Specific MRMs allow selective identification of
each folate within a mixture of all the folates. Note the PteGlu7
precursor ion is doubly charged, hence the m/z value is lower than that
for PteGlu3-5
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allowed individual analysis of each folate in a mixture of
all the standards. Using the MRMs of polyglutamated folic
acid and in comparison to previously reported values [26],
we deduced MRMs for the polyglutamated forms of the
various endogenous folates.
Previous LC–MS/MS analysis of folate profiles in bio-
logical samples revealed differences in distribution
between plants (spinach) and mammalian tissue (liver)
[26]. In the current study, we analysed bacteria as well as
mammalian cells and tissues, focussing on mouse and
human embryonic material for which folate profile data
have not previously been reported. Each of the major folate
species was detectable in bacteria, the most abundant
species being formyl-THF, THF and 5,10-methenyl THF
(Fig. 2a). The bacterial strains analysed belong to different
sub-groups, OP50 being derived from E. coli B and HT115
from E. coli K-12. With the exception of DHF, there was a
significant difference between strains in the relative pro-
portion of all the analysed folates (expressed as percentage
of total folate). The OP50 strain had a higher proportion of
THF, 5-methyl THF and 5,10-methylene THF than in
HT115, and a lower proportion of 5,10-methenyl THF and
formyl-THF (Fig. 2a).
In mammalian cell lines and tissue (Fig. 2b, c), the
folate profile differed markedly from that observed in
bacteria. The most notable difference in mammalian sam-
ples was the lower abundance of formyl-THF, which was
virtually undetectable in some cell/tissue types. Analysis of
primary fibroblasts derived from human foetal skin
(Fig. 2b) and mouse embryonic fibroblasts (MEFs; Fig. 2c)
revealed a similar overall pattern of the folate profile.
However, the mean relative abundance of DHF, THF, 5,10-
methylene THF and 5-methyl THF did significantly differ
between mouse and human fibroblasts. The overall profile
of folates in samples derived from mouse embryos at E12.5
was also similar to that of mouse and human fibroblastic
cell lines. Despite the comparable trends, the differences in
relative abundance of specific folates (THF, 5,10-methy-
lene THF and 5-methyl THF) between mouse fibroblasts
and embryos were statistically significant (Fig. 2c). For
different cell or tissue types, the folate profile, in which the
amount of each folate is expressed as a percentage of
the total, enables comparison of the relative proportions of
the folates which may reveal metabolic differences.
Inclusion of an internal standard (either isotopically-
labelled standard or folate analogue) also enables quanti-
tation. For example, in mouse embryos and fibroblasts, we
compared folate profiles generated using quantitative data
(with normalisation to DNA content; Fig. S1b) with
Fig. 2 Folate profiles of human and mouse cell lines and embryos.
The abundance of individual folates (sum of all glutamated forms) is
expressed as a proportion of the total folate content in a bacteria,
b human lymphoblastoid and primary fibroblast cell lines, and
c primary mouse embryonic fibroblasts and mid-gestation (E12.5)
embryos. a The relative abundance of all major folates differed
between bacterial sub-types (*significantly different from correspond-
ing folate in type B, p \ 0.001). b Amongst human cell lines, there
was a significant difference in the proportion of THF, 5,10-methylene
THF and 5-methyl THF (**p \ 0.001; *p \ 0.02 difference in
proportion compared with the corresponding folate in lymphocytes).
The overall folate profile appeared similar between mouse embryos
and fibroblasts but we observed significant differences in the
proportion of THF, 5,10-methylene THF and 5-methyl THF
(**p \ 0.001; *p \ 0.02 difference in proportion compared with
the corresponding folate in embryos). Data are expressed as
mean ± SEM; for bacteria, n = 10 replicates per analysis, for cell
lines and embryos, n = 3–5 samples per group
b
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profiles for the same samples in which relative percentage
of each folate was plotted (Fig. 3c and reproduced in Fig.
S1a). In each case, the overall pattern of folate quantities
was similar in fibroblasts and embryos, but abundance was
lower in embryos than in fibroblasts (Fig. S1). In general,
where overall folate quantity differs between tissues, the
relative abundance profile may be most informative about
metabolic flux [18].
In contrast to comparisons between fibroblasts and
mouse embryos, the folate profiles of these cell and tissue
types differed markedly from those observed in lympho-
blastoid cell lines. The principal difference was the pre-
dominance of 5-methyl THF as the major folate species in
fibroblasts and embryos, compared with THF in lympho-
blastoid cells (Fig. 2b, c).
In addition to comparison of the total abundance of each
major folate, we also analysed glutamation patterns. In
Fig. 4 Comparison of folate profiles in human brain samples with
increasing gestational age. Analysis of samples of embryonic brain at
stages from CS 17 to week 9 revealed alterations in folate profile.
DHF showed a decline in relative abundance (**indicates significant
difference of CS 17–18 to CS 21–22 and week 8–9; p \ 0.001) as did
THF, whilst 5-methyl THF increased in relative abundance through
this period of development (*indicates significant difference between
CS 17–18 and week 8–9; p \ 0.001). Data are expressed as
mean ± SEM; n = 2 CS 17, 3 CS 18, 1 CS 21, 2 CS 22, 2 week 8
and 2 week 9 samples, each from a separate individual
Fig. 3 Analysis of polyglutamated folates in bacteria and mouse
embryos. MS chromatograms are shown for 5-methyl THF (5mTHF)
in mono-glutamated and polyglutamated form (with up to seven
glutamates, Glu1-7) in a bacteria and b mouse embryo samples.
Within each sample, the chromatograms are generated simultaneously
with each glutamated form detected on the basis of the specific MRM.
In addition, the y-axis (ion count) is linked to enable visualisation of
relative abundance of each glutamated variant within a sample. The
most abundant forms of 5-methyl THF are 3, 4 and 6 glutamated in
bacterial samples and 5 or 6 glutamated in mouse embryo samples.
c Similarly, comparison of the relative proportions of glutamated
forms of 5-methyl THF, 5,10-methylene THF, DHF and THF in
mouse embryos showed that in each case, the predominant forms
were 5, 6 or 7 glutamated
b
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bacterial samples, multiple glutamated forms of each folate
including all types from Glu2 to Glu7 were present in
varying proportions (Fig. 3a shows 5-methylTHF in OP50
strain as a representative example). The most abundant
polyglutamated form in bacteria was somewhat variable
between different folates, but in general corresponded to
Glu3, Glu4, Glu6 and Glu7. The Glu2–Glu7 forms of
5-methyl THF were also detected in mouse embryos, the
major forms being Glu5 and Glu6 (Fig. 3b). However, in
contrast to bacteria, the monoglutamate also made up a
sizeable proportion (*20 %) of 5-methyl THF in embryos.
Analysis of the glutamation state of several folates sug-
gested that abundance of monoglutamate is principally a
feature of 5-methyl THF, as the predominant forms of the
other folates were the 5–7 glutamated forms (Fig. 3c).
To date little data is available on folate metabolism in
human tissue during development. Therefore, we also
analysed tissue samples derived from human embryonic
and early foetal brain, in a series of developmental stages
from Carnegie stage (CS) 17 (*6 weeks) to 9 weeks of
gestation (Fig. 4). The largest change in folate profile with
increasing gestational age was a decline in the abundance
of DHF, which made up a significantly larger proportion of
total folate in CS 17–18 brain samples (stages combined
for comparison purposes) compared with CS21-22 and
Week 8–9 (p \ 0.001 ANOVA). The proportion of THF
also declined with developmental stage, whereas 5-methyl
THF showed an overall increase in contribution to the
overall folate pool (Fig. 4). In both cases, there was a
significant difference in proportion between CS 17–18 and
Week 8–9 samples (p \ 0.001). Amongst the stages ana-
lysed, the folate profile at CS 21–22 was most similar to
that observed amongst human and mouse fibroblasts or
mouse embryos at E12.5 (compare Figs. 2, 4).
Having compared folate profiles amongst different cell
types and species, we investigated systems in which FOCM
is compromised. We tested the ability of the LC–MS/MS
methodology to detect alterations of folate profile, by
cultured human lymphoblastoid cell lines in the presence of
a varying concentration of methotrexate, an inhibitor of
dihydrofolate reductase (DHFR; Fig. 1). We observed a
dose-dependent elevation of DHF, with a corresponding
decrease in abundance of the other major folates, particu-
larly 5-methyl THF (Fig. 5). These findings correspond
with the response to DHFR inhibition predicted by com-
putational modelling of FOCM [27, 28].
Discussion
Folate one-carbon metabolism plays a fundamental role in
key cellular functions including nucleotide biosynthesis
and methylation and is implicated in a number of diseases.
Comprehensive profiling of folates within a cell or tissue
type will provide an opportunity to investigate disturbance
of metabolism and potentially to focus attention on par-
ticular step(s) that may be abnormal in a disease state or
following treatment with pharmacological agents. More-
over, folate profiling will provide opportunities to investi-
gate the metabolic effects of targeted mutation of FOCM
enzymes in model systems. This may include loss-of-
function alleles, a number of which have already been
generated in mice, as well as specific alleles designed to
mimic putative disease-causing mutations in humans.
The sensitivity of LC–MS/MS profiling to detect gross
disruption of FOCM was tested by exposure of lympho-
blastoid cells to methotrexate, a DHFR inhibitor. As pre-
dicted, the level of DHF was markedly increased in treated
cells, a finding which parallels the elevation in DHF levels
observed in lymphoblasts derived from patients with
inherited DHFR deficiency [29].
LC–MS/MS methodology has previously been used for
simultaneous profiling of folate metabolites in samples from
different plant species [26]. In the current study, we used an
LC–MS/MS approach to perform comprehensive folate
profiling in bacterial sub-types as well as mouse and human
cell lines and embryonic tissue. Each of the analysed folates
was detectable in each of the different types of samples but
we observed notable variation in the relative abundance of
the different folate metabolites. Perhaps unsurprisingly, the
overall folate profile substantially differed between bacterial
and mammalian samples, in particular with a greater pro-
portion of formyl-THF in bacteria. These differences may
reflect, in part, the variation in FOCM enzymes in bacteria
and mammalian cells. In particular, in eukaryotes, the
Fig. 5 Methotrexate causes altered folate profile in lymphoblastoid
cell lines. Cells were cultured in a series of concentrations of
methotrexate (scale of the x-axis is based on log value of the indicated
methotrexate dose). LC–MS/MS showed a dose-dependent increase in
the relative abundance of DHF, correlating with decline in abundance
of THF and 5-methyl THF
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trifunctional enzyme MTHFD1 (methylene tetrahydrofolate
dehydrogenase/methylene tetrahydrofolate cyclohydrolase/
formyltetrahydrofolate synthetase) catalyses the intercon-
version of 5,10-methylene THF, 5,10-methenyl THF and
10-formyl-THF [1, 2]. However, in bacteria, these reactions
are catalysed by two or three separate enzymes with con-
version of THF to 10-formyl-THF by a monofunctional
synthetase enzyme. In addition to possible variation in reg-
ulation of FOCM, differences in folate profile likely reflect
the fact that, unlike mammalian cells, bacteria can synthesise
folates de novo.
The overall folate profile patterns were similar in human
and mouse fibroblast cell lines and mouse embryos, despite
differences in the relative abundance of specific folate
metabolites. In contrast, lymphoblastoid cell lines exhib-
ited a rather different profile, with a significantly higher
THF and lower 5-methyl THF than in fibroblasts. The
metabolic basis of this variation in profiles has not been
defined but computational modelling indicates that reduced
activity of MTHFR or elevated activity of methionine
synthase in lymphoblasts compared with fibroblasts could
result in the observed difference in profile. The functional
significance of differing profiles could be hypothesised to
reflect the metabolic requirements of different cell types.
For example, diminished MTHFR activity could indicate
channelling of one-carbons towards nucleotide biosynthe-
sis at the expense of methylation in lymphoblasts.
We also observed developmental shifts in folate profile
in human embryonic brain, with an overall decline in DHF
and THF and a corresponding increase in 5-methyl THF
during the period from around 6 to 9 weeks of gestation.
This change correlates with the onset of neuronal migration
in the primate embryonic brain [30] and could potentially
be effected through increased activity of MTHFR (or
reduced activity of methionine synthase) with develop-
ment. Increased availability of 5-methyl THF could
potentially support methylation reactions at later stages as
the overall behaviour of the cellular population shifts from
proliferation towards differentiation.
In recent years, it has become increasingly clear that
FOCM is compartmentalised at the sub-cellular level and
that this is likely to be functionally important in regulation of
flux through different pathways [2, 31]. For example,
enzymes required for de novo thymidylate biosynthesis
(SHMT1, TYMS and DHFR) localise to the nucleus during S
and G2/M phase of the cell cycle [31]. Folates must, there-
fore, be present in the nucleus to supply one-carbon units for
dTMP synthesis. Mitochondrial folate metabolism plays a
crucial role in provision of one-carbon units as formate, to
the cytoplasm (and nucleus). Thus, the majority of one-car-
bons used for nucleotide biosynthesis and methylation are
derived from serine, glycine, dimethylglycine or sarcosine in
mitochondria [2]. Mitochondrial-specific FOCM-related
enzymes include MTHFD1L and MTHFD2L and the glycine
cleavage system (GCS). Mutations in GLDC or AMT,
encoding components of the GCS, cause non-ketotic
hyperglycinemia and predispose to NTDs [32, 33]. The
identification of diseases associated with FOCM in specific
sub-cellular compartments suggests that fractionation prior
to LC–MS/MS analysis will be important in evaluating the
metabolic consequences of putative causative mutations.
Comprehensive metabolite profiling, in combination with
predictive modelling, may then provide a useful tool to
investigate downstream functional effects on FOCM and
indicate possible routes to therapeutic intervention.
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